Analyst Price Target is $35.72
▼ -6.54% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Dicerna Pharmaceuticals in the last 3 months. The average price target is $35.72, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -6.54% upside from the last price of $38.22.
Current Consensus is
The current consensus among 10 contributing investment analysts is to hold stock in Dicerna Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.